Goldman Sachs raised the firm’s price target on Crinetics (CRNX) to $45 from $40 and keeps a Neutral rating on the shares.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRNX:
- Crinetics Pharma’s Positive Earnings Call Highlights PALSONIFY Success
- Crinetics Pharmaceuticals: Strong Market Entry and Financial Position Support Buy Rating
- Crinetics price target lowered to $108 from $143 at Citizens JMP
- Crinetics Pharmaceuticals Reports Positive Launch and Financials
- Crinetics reports Q3 EPS ($1.38), consensus ($1.25)